Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients
Truvada PrEP causes only mild loss of bone mineral density
People with hepatitis C have higher cancer rates, even when excluding liver cancer
Modern NNRTI regimens can be effective with 85% adherence
Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis